ETF Holdings Breakdown of KNSA

News associated with KNSA

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Trading Down 5.4% After Insider Selling

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Free Report)’s share price traded down 5.4% during trading on Thursday after an insider sold shares in the company. The stock traded as low as $28.44 and last traded at $28.60. 434,756 shares changed hands during trading, a decline of 14% from the average session volume of 508,421 shares. […] - 2025-06-13 05:19:05

26,808 Shares in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Bought by Squarepoint Ops LLC

Squarepoint Ops LLC acquired a new position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 26,808 shares of the company’s stock, valued at approximately $530,000. Other large investors have also recently added to […] - 2025-06-04 08:04:47

Bank of America Corp DE Has $4.27 Million Stock Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Bank of America Corp DE increased its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report) by 2.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 215,772 shares of the company’s stock after buying an additional 4,654 shares during […] - 2025-05-30 07:31:00

Lazard Asset Management LLC Buys Shares of 3,098 Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Lazard Asset Management LLC acquired a new position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 3,098 shares of the company’s stock, valued at approximately $61,000. Several other large investors have also recently made changes […] - 2025-05-26 07:50:58

BNP Paribas Financial Markets Sells 19,446 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

BNP Paribas Financial Markets cut its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report) by 10.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 173,480 shares of the company’s stock after selling 19,446 shares during the period. BNP Paribas […] - 2025-05-15 08:36:54

Tower Research Capital LLC TRC Grows Stock Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Tower Research Capital LLC TRC lifted its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report) by 117.1% during the fourth quarter, Holdings Channel reports. The institutional investor owned 8,483 shares of the company’s stock after buying an additional 4,575 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Kiniksa Pharmaceuticals were worth […] - 2025-05-07 08:32:54

Invesco Ltd. Sells 41,380 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Invesco Ltd. reduced its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report) by 74.6% during the fourth quarter, Holdings Channel reports. The institutional investor owned 14,108 shares of the company’s stock after selling 41,380 shares during the quarter. Invesco Ltd.’s holdings in Kiniksa Pharmaceuticals were worth $279,000 at the end of the […] - 2025-05-05 08:00:54

Wells Fargo & Company MN Has $417,000 Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Wells Fargo & Company MN increased its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report) by 54.7% in the fourth quarter, HoldingsChannel reports. The firm owned 21,102 shares of the company’s stock after buying an additional 7,463 shares during the period. Wells Fargo & Company MN’s holdings in Kiniksa Pharmaceuticals were worth […] - 2025-05-05 07:22:58

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Trading Up 4.9% Following Strong Earnings

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Free Report)’s stock price was up 4.9% during mid-day trading on Wednesday after the company announced better than expected quarterly earnings. The company traded as high as $27.15 and last traded at $27.15. Approximately 869,131 shares were traded during mid-day trading, an increase of 83% from the average daily […] - 2025-05-01 07:26:57

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Shares Gap Up After Strong Earnings

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Free Report)’s stock price gapped up before the market opened on Tuesday following a stronger than expected earnings report. The stock had previously closed at $21.47, but opened at $22.55. Kiniksa Pharmaceuticals shares last traded at $25.01, with a volume of 81,859 shares trading hands. The company reported $0.11 […] - 2025-05-01 05:18:54

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says

Kiniksa Pharmaceuticals (NASDAQ:KNSA – Free Report) had its price objective raised by Jefferies Financial Group from $40.00 to $45.00 in a report published on Tuesday morning,Benzinga reports. Jefferies Financial Group currently has a buy rating on the stock. A number of other research firms also recently commented on KNSA. Citigroup began coverage on Kiniksa Pharmaceuticals […] - 2025-04-30 07:56:50

Legal & General Group Plc Has $816,000 Stock Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Legal & General Group Plc cut its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report) by 18.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 41,267 shares of the company’s stock after selling 9,064 shares during the quarter. Legal & General Group Plc’s […] - 2025-04-28 08:02:52

JPMorgan Chase & Co. Buys 277,827 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

JPMorgan Chase & Co. boosted its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report) by 138.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 477,800 shares of the company’s stock after purchasing an additional 277,827 shares during the period. JPMorgan […] - 2025-04-15 08:08:56

Wellington Management Group LLP Buys 22,096 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Wellington Management Group LLP raised its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report) by 46.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 69,813 shares of the company’s stock after purchasing an additional 22,096 shares during the quarter. […] - 2025-04-14 08:27:05

Sei Investments Co. Has $834,000 Stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Sei Investments Co. trimmed its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report) by 5.3% during the 4th quarter, HoldingsChannel reports. The firm owned 42,184 shares of the company’s stock after selling 2,354 shares during the quarter. Sei Investments Co.’s holdings in Kiniksa Pharmaceuticals were worth $834,000 at the end of the […] - 2025-04-09 07:28:48

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives Average Rating of “Buy” from Analysts

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Free Report) has earned an average recommendation of “Buy” from the six analysts that are covering the firm, MarketBeat reports. Six investment analysts have rated the stock with a buy rating. The average 12 month price objective among brokers that have issued ratings on the stock in the last […] - 2025-04-07 08:22:59

Principal Financial Group Inc. Sells 25,944 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Principal Financial Group Inc. lowered its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report) by 49.1% during the 4th quarter, HoldingsChannel reports. The firm owned 26,907 shares of the company’s stock after selling 25,944 shares during the period. Principal Financial Group Inc.’s holdings in Kiniksa Pharmaceuticals were worth $532,000 as of its most recent […] - 2025-03-07 08:17:04

Y Intercept Hong Kong Ltd Purchases Shares of 13,050 Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Y Intercept Hong Kong Ltd acquired a new stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 13,050 shares of the company’s stock, valued at approximately $258,000. A number of other institutional investors also recently modified […] - 2025-03-05 11:01:16

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Bought by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. grew its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report) by 12.9% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 8,814 shares of the company’s stock after acquiring an additional 1,004 shares during the quarter. China Universal Asset […] - 2025-02-04 09:15:10

KNSA institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-06-26	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	33,055	USD 941,737 0.4%
2025-06-26	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	6,176	USD 175,954
2025-06-26	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	21,128	USD 601,937
2025-06-26	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	21,128	USD 601,937
2025-06-26	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	52,404	USD 1,492,990
Total =		133,891	USD 3,814,555

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer